Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (3260)	3/24/2021 6:53:13 PM
From: CuttingEdge Bio	Read Replies (1) \| Respond to of 3557

Is it really viable to run ANOTHER trial like this one that just read out on thousands of patients proving the efficacy of the IV treatment, in order to prove the SubQ of the same drug also works the same on outcomes????? It took over a year to get to this point. There is no way that's happening. And not a reasonable standard to expect it. If they can show the PK is sufficiently similar and the viral load impact is the same, there is no reason to believe the SubQ will be behaving any differently for the question of outcomes!